StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
No sell-side coverage available for DTIL yet.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-15 | $8.01 | $7.27 | -9.24% | 0.2M |
| 05-18 | $7.31 | $6.96 | -4.79% | 0.4M |
| 05-19 | $6.96 | $6.90 | -0.86% | 0.2M |
| 05-20 | $6.95 | $7.18 | +3.31% | 0.2M |
| 05-21 | $7.30 | $7.15 | -2.05% | 0.1M |
Precision BioSciences Inc clinical stage gene editing company utilizing its proprietary ARCUS platform to concurrently develop two clinical-stage in vivo gene editing therapies. The ARCUS platform is used to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion (inserting DNA into gene to cause expression/add function), elimination (removing a genome, e.g. viral DNA), and excision (removing a large portion of a defective gene by delivering two ARCUS nucleases in a single adeno-associated virus ("AAV")).
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $10.84M | $34.26M | $60.00K | $47.00K |
Operating Income | $-9.07M | $-52.15M | $-64.66M | $-43.99M |
Net Income | $-18.44M | $-45.72M | $-65.86M | $-23.52M |
EPS (Diluted) | $-0.75 | $-3.56 | $-6.14 | $-4.33 |
Total Assets | $143.89M | $154.42M | $93.51M | $108.93M |
Total Liabilities | $67.79M | $62.17M | $76.88M | $74.87M |
Cash & Equivalents | $99.37M | $110.82M | $44.87M | $62.24M |
Free Cash Flow OCF − CapEx | $-11.96M | $-65.93M | $-54.66M | $-39.39M |
Shares Outstanding | 25.81M | 24.09M | 12.08M | 11.64M |
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.